ROS1 and lung cancer: Improved understanding of the biology of lung cancer has resulted in the development of new biomarker-directed therapies targeting molecular alterations (eg, EGFR mutations, ALK rearrangements, ROS1 rearrangements, and BRAF V600E mutations), which have prolonged survival of lung cancer patients 3.